FILE PHOTO: A handout photo provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against the coronavirus disease (COVID-19) developed by the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, Russia August 6, 2020. Picture taken August 6, 2020. The Russian Direct Investment Fund (RDIF)/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE WAS PROVIDED BY A THIRD PARTY. NO RESALES. NO ARCHIVES. MANDATORY CREDIT.
(Reuters) - Russia's granting of regulatory approval to a COVID-19 vaccine after less than two months of human testing has prompted expressions of caution as well as interest from around the world.
Moscow said on Wednesday that the first batch of the vaccine would be ready for some medics within two weeks and rejected safety concerns as "groundless".
